Business Context and Reporting Period
This Form 8-K, dated January 16, 2026, serves as a supplement to the Joint Proxy Statement/Prospectus regarding the proposed merger between Kenvue Inc. and Kimberly-Clark Corporation (K-C). The filing was issued to address stockholder litigation and demand letters alleging material omissions in prior disclosures. The Kenvue Board continues to unanimously recommend that stockholders vote "FOR" the merger proposals at the special meeting scheduled for January 29, 2026.
Key Financial Metrics and Projections
The filing provides unaudited prospective financial information and valuation analysis for the period 2025–2030. Key metrics include:
- Kenvue Standalone Projections (2026E): Revenue of $15.448 billion; Adjusted EBITDA of $3.565 billion; Unlevered Free Cash Flow of $2.114 billion.
- K-C Standalone Projections (2026E): Revenue of $16.988 billion; Adjusted EBITDA of $3.705 billion; Unlevered Free Cash Flow of $1.331 billion.
- Debt and Liquidity (as of Q3 2025):
- Kenvue Net Debt: $7.902 billion.
- K-C Net Debt: $5.369 billion.
- Pro Forma Combined Net Debt: $15.994 billion.
- Valuation Ranges (Implied Equity Value per Share):
- Kenvue (Centerview DCF): $23.34 to $28.96.
- Kenvue (Goldman Sachs DCF): $20.59 to $30.08.
- K-C (Centerview DCF): $136.93 to $167.83.
Material Changes and Supplemental Disclosures
This filing supplements the Joint Proxy Statement/Prospectus with the following material updates:
- Strategic Review Committee: Disclosed the formation of a Kenvue board committee on June 30, 2025, to evaluate strategic alternatives, clarifying it was formed for convenience and not due to a conflict of interest.
- Legal Counsel Conflicts: Clarified that K-C engaged Gibson Dunn for product liability due diligence because Kenvue's counsel (Kirkland & Ellis) represented Kenvue in product liability matters. Kenvue accounted for less than 1.0% of Kirkland's revenue.
- Financial Advisor Fees: Disclosed that J.P. Morgan received approximately $24.0 million in aggregate fees from Kenvue and $11.0 million from K-C over the preceding two years. J.P. Morgan anticipates receiving approximately $23.4 million in financing fees related to the transaction.
- Comparable Company Analysis: Updated valuation multiples, showing Kenvue trading at 9.9x implied 2026 EBITDA versus a median of 13.6x for selected peers.
Outlook, Risks, and Contingencies
Management Commentary: Management asserts that the merger creates significant value through cost and growth synergies. The filing includes detailed synergy projections and combined company financial forecasts.
Legal Risks: The filing addresses multiple lawsuits (Wisconsin, New Jersey, New York, and Delaware) seeking to enjoin the merger or demand corrective disclosures. Kenvue voluntarily amended disclosures to mitigate the risk of delay or termination of the transaction.
Forward-Looking Risks: The filing warns that actual results may differ due to integration challenges, failure to realize synergies, regulatory approvals, credit rating downgrades, product liability claims, and macroeconomic factors including inflation and supply chain disruptions.
Investor Verification Checklist
- Verify the status of the stockholder vote scheduled for January 29, 2026, and whether the litigation has been stayed or dismissed.
- Review the Joint Proxy Statement/Prospectus in its entirety, as this 8-K is a supplement and not a standalone document.
- Assess the pro forma debt load of approximately $16 billion and the impact on the combined company's credit rating.
- Examine the non-GAAP reconciliations for Adjusted EBITDA and Unlevered Free Cash Flow, noting that no GAAP reconciliation is provided in this filing.
- Confirm the exchange ratio of 0.14625x plus $3.50 cash per share against current analyst price targets (Kenvue median: $20.00; K-C median: $132.00).